Previous Annual Addresses

Institute Annual Addresses.

2024

UCL Queen Square Institute of Neurology celebrates achievements at 60th Annual Address

A review of the year by Professor Michael Hanna (Director of UCL Queen Square Institute of Neurology), followed by the Annual Address by Professor Patrick Chinnery (Executive Chair, MRC) 

Review of the year

Professor Hanna began by welcoming the speakers and Aimie Chapple, UCL Vice-President (Operations) and thanking the ION leadership and Professional Services team for their contributions over the past year, and acknowledged support from the Faculty and Divisions, and all our external partnerships and supporters.

He paid specific thanks to staff who had left ION in 2024, including Dr Rina Bandopadhyay, Latha Rowles, Robert Courtney and Kamlyn Ramkissoon, and the loss of esteemed colleagues Professor Richard Orrell and David G.T. Thomas.

Professor Hanna highlighted the significant progress made over the past year. The ION published nearly 1,900 peer-reviewed articles, and currently holds over £350m in active grant funding. 

He showcased wide-ranging examples of ION’s research impact and initiatives including an influential early paper on the neurological impact of COVID-19, development of SPM software, Queen Square MND Centre Symposium, surgical robotics, ALS disease mechanisms, Optimas stroke trial, plasma biomarkers for dementia diagnosis, re-purposing ambroxol in Parkinson’s Disease, the EJS ACT-PD platform, EpilepsyGTx spinout, innovative MS trial designs, and the opening of the Rare Dementia Support Centre in 2025. 

Professor Hanna highlighted our Translation and Enterprise activities, including the work of LWENC and the first gene-silencing drug in Alzheimer’s disease, the Genetic Therapy Accelerator Centre, led by Professor Francesco Muntoni, and the UCL Spinout AstronauTx. He also highlighted the new Neuroscience, Cancer and Hearing Advanced Therapy Research Pharmacy and Queen Square Clinical Trials Centre which are due to launch in 2025. He also gave an update on the dual hub for translational neuroscience on Grays Inn Road which will open in 2026, including core technology platforms.

These achievements were complemented by many individual ION researchers’ awards and appointments, including Professor Sarah Tabrizi’s election to US National Academy of Medicine and as Fellow of the Royal Society, Sir Demis Hassabis’ Nobel Prize, Professor Gillian Bates’ Royal Society Medal, Professor Mary Reilly’s Alan J. Gebhart Prize, Professor Kailash Bhatia’s appointment as the European Academy of Neurology President-Elect, Professor Andrea Malaspina’s Healey International Prize for Innovation in ALS, and Dr James Sleigh’s MRC Senior Clinical Fellowship, alongside 100% success in 2024 senior and early career promotions.

Professor Hanna also highlighted ION-wide EDI initiatives, including EDI awards, as well as Educational achievements, including the new Human Neuroscience BSc, and ION’s sustainability initiatives, including the Hot Brain Conference, organised with Lancet Neurology.

All these achievements are covered in the ION Annual Review which was launched at the event.

Professor Hanna then awarded the Queen Square Essay Prize to Dr Kyriakoula Varmpompiti. 

Professor Hanna concluded by looking back at the innovation and impact of the ION in the 47 years since Queen Square House was opened, including thrombolysis treatment, diagnostic neurogenetics, pioneering MRI and DBS and epilepsy surgery. He highlighted the success factors which will be realised in the future at the translational neuroscience facility on Gray’s Inn Road.

He then introduced Professor Patrick Chinnery’s Annual Address. 

Annual Address

We were delighted to welcome as the guest speaker Professor Patrick Chinnery, Executive Chair, MRC: “Medical Research - dial 111”.

Professor Patrick Chinnery gave a thoughtful and wide ranging commentary, starting with his connections to Queen Square, where he undertook his PhD viva with Dr John Morgan Hughes: whose neurogenetics research, along with Professor Anita Harding and P.K. Thomas, is the type of research he feels the MRC should be supporting in the present day. 

He gave an overview of the history of the MRC - now in it’s 111th year - from Walter Morley Fletcher, through the Haldane Report, to Henry Dale and the NIMR, and MRC Units around the country. He detailed how discovery science has been central to its purpose from the start, and what we can learn from this today: the sub-title of his talk being “what goes around comes around” .

He identified the next big challenges for medical research, including the emerging public health crisis of neurological disorders; and the complex and challenging funding landscape. He highlighted how MRC should recognise its distinctive role: in funding high risk, high reward, mechanistic science, which drives translation. He emphasised the importance of partnerships, with NIHR, industry and universities, and UKRI investment in initiatives including the UK Biobank and Health Data Research Network, and the development of MRC Centres of Research Excellence. 

He closed with a focus on the declining clinical research workforce, and its related drivers, disincentives and new pressures, and a forthcoming action plan to address these.

Vote of Thanks

Closing remarks were given by Professor Michael Hanna, following the vote of thanks by Professor Geraint Rees, UCL Vice-Provost (Research, Innovation & Global Engagement)

Professor Rees started by reflecting on the immense impact of ION research, and the complex challenges for funders in a changing demographic landscape and global ecosystem. 

He specifically thanked Professor Chinnery for the MRC’s longevity and indefatigability; for showing the importance of how medical research is conducted; and for his leadership.

Links

 

2023

A review of the year by Professor Michael Hanna, Director of UCL Queen Square Institute of Neurology, followed by the Annual Address by Sir Patrick Vallance on “Why governments need science” with a vote of thanks by Dr Michael Spence AC, UCL President and Provost.

Review of the year

Professor Hanna thanked the ION leadership and Professional Services team for their contributions over the past year, and acknowledged support from the Faculty and Divisions, and all our external partnerships and supporters.

He paid specific thanks to staff who had left ION in 2023, including David Blundred and Caroline Selai, and welcomed new staff including Professor Fiona Ducotterd as the new Chief Scientific Officer of the ARUK Drug Discovery Institute, and the appointment of Professor Siddharthan Chandran as the new UK DRI director, based at the UK DRI HQ at UCL.

Professor Hanna highlighted the significant progress made over the past year. The ION published over 1900 peer-reviewed articles, and had its most successful year in terms of grant income, securing over £50m in new grants and currently holding over £350m in active grant funding. He emphasised the teams’ global influence, presenting findings at major international conferences and collaborating locally, nationally, and internationally.

He showcased wide-ranging examples of ION’s research impact and initiatives including the use of AI in improving safety in neurosurgery, trials in Huntington’s Disease, ALS disease mechanisms, functional anatomy of the visual cortex, tissue hypoxia and biomarkers in MS, the new MND Research Institute and the EJS ACT-PD platform. 

Professor Hanna highlighted our Translation and Enterprise activities, including the work of LWENC and the first gene-silencing drug in Alzheimer’s disease, leadership in translational genomics, including the establishment of a new Genetic Therapies Accelerator Group, led by Professor Francesco Muntoni, and UCL Spinout AstronauTx with Alzheimer’s Research UK UCL Drug Discovery Institute (UCL DDI). He also highlighted the new Neuroscience, Cancer and Hearing Advanced Therapy Research Pharmacy due to launch in 2024. He also gave an update on the £281m translational neuroscience facility on Grays Inn Road which will open in the 24/25 academic year, including the Topping Out ceremony.

These achievements were complemented by many individual ION researchers’ awards and appointments, including the MRC Millennium medal, new Fellows of the Academy of Medical Sciences, and AES awards, alongside 100% success in 2023 senior and early career promotions.

Professor Hanna also highlighted ION-wide EDI initiatives, as well as Educational achievements, including the new iBSc and Human Neuroscience BSc, and ION’s sustainability initiatives, including the Hot Brain Conference.

All these achievements are covered in the ION Annual Review which was launched at the event.

He concluded by looking back at the innovation and impact of the ION in the 46 years since Queen Square House was opened, including thrombolysis treatment, diagnostic neurogenetics, amyloid hypothesis, pioneering MRI and DBS and epilepsy surgery. He highlighted the success factors which will be realised in the future at the translational neuroscience facility on Gray’s Inn Road.

Professor Hanna ended by congratulating Queen Square Essay Prize award winners Dr Oliver Ziff and Dr Angelo Dawson, before introducing Sir Patrick Vallance’s Annual Address. Link

Annual Address

We were delighted to welcome as the guest speaker Sir Patrick Vallance, Chairman of the Natural History Museum, formerly Government Chief Scientific Adviser. “Why governments need science”.

Sir Patrick Vallance (a UCL Alumni) gave a thoughtful and wide ranging commentary, starting with emphasising how science underpins all aspects of government policy, from food to town planning, before assessing the strengths and weaknesses of science in academia, government and industry in the UK. He showed how each plays a pivotal role in times of emergency, exemplified by the COVID pandemic and the climate crisis.

Sir Patrick ended with examples from his current role at the Natural History Museum, and the future work of the Advanced Research and Invention Agency. He closed by emphasising the importance of diversity in recruitment and teams in delivering science

Vote of Thanks

Closing remarks were given by Professor Michael Hanna, following the vote of thanks by Dr Michael Spence AC, UCL President & Provost. Dr Spence highlighted the need for effective scientific communicators and synthetic intelligence, as exemplified in the Annual Address. 

Links

2022

A review of the year by Professor Michael Hanna, Director of UCL Queen Square Institute of Neurology, followed by the Annual Address by Dame Anne M. Johnson, Professor of Infectious Disease Epidemiology, and President of the Academy of Medical Sciences.

Review of the year

Professor Michael Hanna began by thanking everyone for all their work over the past two years, including impactful COVID-19 research - 25 PIs have been involved in 145 papers, from early highly cited papers in March 2020 to apps to support patients in the stroke service. 

Professor Hanna highlighted achievements over the past year, including successful £90m renewal of UCLH BRC, and the Dementia theme and Translational Neuroscience themes which are based at ION, Leonard Wolfson Experimental Neurology Centre’s successful £10m NIHR CRF bid for 2022-27, and UK DRI’s Quinquennial Review. 

Professor Hanna thanked the ION leadership and Professional Services team for their contributions over the past year, and acknowledged support from the Faculty and Divisions, and all our external partnerships. He paid specific thanks to staff who had left ION in 2022, including Libby Bertram and Paul Whiting. 

He also highlighted ION’s impressive research output: increased peer review publications, as well as success in the REF2021, and the highest number of active grants including 9 grants of over £1m and 14 over £500k, and £15m income from Enterprise activities.

Professor Hanna showcased wide-ranging examples of ION’s research impact, including novel therapeutic targets for ALS, MRI guided focused ultrasound, an intensive comprehensive aphasia programme, brain charts over the lifespan, the new UK DRI fluid biomarker platform, multi-stage multi-arm MS trials, gene therapy for brain circuit disorders, the Huntington’s Disease REF impact case study, and primary human mitochondrial disease research.  

ION’s Science Away Day had reviewed ION’s strategic plan with its emphasis on actively translating knowledge, and Professor Hanna highlighted our Translation and Enterprise activities, supported by the new Translational Research manager, and the Symposium which took place before this Annual Address. He also emphasised ION’s gene therapy research, including plans for a new gene therapy accelerator centre.

Professor Hanna also gave an update on the creation of the world-class centre of excellence in neuroscience on Grays Inn Road, including the burial of a time capsule in May 2022.

These achievements were complemented by many individual ION researchers’ awards and appointments, including a knighthood for Professor Sir John Hardy, and new Fellows of the Academy of Medical Sciences and the British Academy, alongside success in 2022 senior and early career promotions, and a Wellcome Career Development Award.  

Professor Hanna also highlighted ION-wide EDI initiatives, with 12% of ION staff involved in EDI activities, as well as Educational achievements and scholarships, and ION’s sustainability initiatives, including Professor Sanjay Sisodiya’s work on Climate Change and Epilepsy. He closed by awarding the Queen Square Essay Prize to Kanza Tariq, and introducing Dame Anne M. Johnson’s Annual Address. 

Annual Address

We were delighted to welcome as the guest speaker Dame Anne M. Johnson MD, FMedSci, FFPH, FRCP, FRCGP, Professor of Infectious Disease Epidemiology & President of the Academy of Medical Sciences ‘Making Medical Science work for everyone: What is the role of a National Academy’

Dame Anne’s Address focused on three strands of the Academy of Medical Sciences’ strategy: Policy, People, Communications. 

She began with an overview of the Academy’s role in influencing policy with an evidence based approach, including recent examples on investment in Science, Horizon Europe, COVID-19 Winter Reports, Future of Public Health and the NHS-Academia Interface; 

Dame Anne’s second strand focused on People: and the Academy’s support for the next generation of researchers, across the whole spectrum, from undergraduates onwards, including starter grants for clinical lecturers, Sustain: enabling female researchers to thrive, and the FLIER leadership programme.

In the final strand, Communications, she emphasised the need for meaningful PPI, including digital communications, as well as workshops and reference groups, with initiatives such as the People’s Perspective report, young adults DIVOC-91 comic book, and Departure Lounge pop-ups. 

Dame Anne ended with an overview of future challenges in supporting UK R&D, and new activities for the Academy, including cross-sector schemes, sustainability of health research, and the UK Young Academy, and closed with an encouragement and suggestions for how attendees can get involved in the Academy’s work. 

Vote of Thanks

The vote of thanks was given by Professor Linda Greensmith, Head of Department, Neuromuscular Diseases, UCL Queen Square Institute of Neurology. As a Fellow of the Academy of Medical Sciences, Professor Greensmith thanked Dame Anne as the first female president of the Academy for such a thought provoking and timely lecture. Professor Greensmith also thanked the organisers of the Symposium which preceded the Annual Address.

Links

2021

This year’s annual address began with a review of the year by Professor Michael Hanna, Director of UCL Queen Square Institute of Neurology, followed by the Annual Address by UCL President & Provost, Dr Michael J Spence AC & vote of thanks by Dr Helene Crutzen, Institute Manager.

Review of the year

Professor Hanna highlighted ION activities over the past year, including contributions to COVID research, pivoting to online learning and staff volunteering in hospitals and vaccination centres. COVID research included emerging spectrum of COVID 19 neurology, understanding vaccine associated cerebral venous thrombosis, and genetic links between Alzheimer’s Disease and severe COVID outcomes, alongside innovations in effective therapy and support, e.g. N-ROL tele-rehabilitation service. Professor Hanna thanked the ION leadership and Professional Services team for their contributions over the past year, welcomed our four new Deputy Directors, and acknowledged support from the Faculty and Divisions, and all our external partnerships. 

He also highlighted ION’s impressive research output: increased peer review publications, including over 130 publications on COVID-19, and highly cited researchers, as well as the REF submission, and major grants: 14 grants of over £1m and 12 over £500k, £15m active enterprise grants and spinouts.

Professor Hanna showcased wide-ranging examples of ION’s research impact, from algorithms in epilepsy surgery, SUDEP risk tool and the Octopus MS trial, to RNA biology and biomarkers in MND, and discovery science at UK DRI at UCL .

The ION recently held a PI Science Away day which highlighted all departments’ engagement in bidirectional translational research. Professor Hanna highlighted the translational work at Leonard Wolfson Experimental Neurology Centre, including antisense therapies for Huntington’s Disease, and pre-clinical gene therapies for epilepsy, spasticity and MND, the construction of the dual hub for UCL translational neuroscience, which held a ground breaking ceremony in May 2021, and the appointment of the Deputy Director for Enterprise, Translation and Advanced Therapeutics.

These achievements were complemented by many individual IoN researchers’ awards and appointments, including new Fellows of Academy of Medical Sciences and Royal Society, alongside success in 2021 senior and early career promotions.  

Professor Hanna also highlighted ION-wide EDI initiatives, including successful renewal of Athena SWAN Silver award, mentoring scheme and award, as well as Educational achievements, including success in PRES results, new PhD fellowships and PhD supervisor award to Professor Schiavo, and the ION’s sustainability initiatives, including the development of the UCL NeuroClimate Consortium.

He congratulated all our students on their recent graduation.

Annual Address

We were delighted to welcome as the guest speaker UCL President & Provost, Dr Michael J Spence AC on “Universities and a health system for the future”. Dr Spence began by highlighting the impact of changing demographics, rising inequalities and costs of technologies and care, and the shifts in demand, placing pressures on healthcare systems. He discussed how they might face these through increased multi-disciplinary approaches and engagement with partners, and increased health systems and management research.

Dr Spence emphasised the complexities and challenges in bringing together multiple disciplines and partners, including career structures, resourcing, communication and leadership. He cited existing examples of best practice at UCL, how UCL cross-working increases the impact on public health and quality of life, and his commitment to the whole of the University being stronger together.

Vote of Thanks

The event closed with a vote of thanks by Dr Helene Crutzen, Institute Manager, who reflected on her past six years in office, particularly Professional Services and ION cultural changes during that time, as well as the contributions of the Professional Services team over the past two years. 

Links

2020

This year’s annual address on 14th December 2020, with 275 virtual attendees, began with a review of the year presented by Professor Michael Hanna, Director of UCL Queen Square Institute of Neurology, followed by Education Prizes and Annual Address given by Dr Richard J Youle.

Review of the year

Professor Hanna showcased wide-ranging examples of IoN’s research impact, from COVID-19 and stroke and the N-ROL collaboration with SameYou charity, to gene therapy for refractory focal epilepsy and gene discovery in SORD neuropathy, to the MS-SMART trial and anti-sense oligonucleoside trials at LWENC, DRC cohort studies and public engagement and the HD-YAS study. He also highlighted IoN’s impressive research output: one paper every 5 hours on average, including over 60 publications on COVID-19, with 11 out of the 45 of UCL’s Highly Cited Researchers being at IoN.

Highlights from the year included the renewal of the Wellcome Centre for Human Neuroimaging and ARUK DDI funding, and of the International Max Planck Research School; major grants, including £19m Aligning Science Across Parkinson’s (ASAP) funding, £10m for International Brain Lab; £12.5m investment in ION enterprise; and ION-DRI programme, including a number of new initiatives to improve laboratory support and ways of working and new IoN-DRI website.

These achievements were complemented by many individual IoN researchers’ awards and appointments, including new Fellows of the Royal Society and Academy of Medical Sciences, alongside 100% success in 2020 senior promotions, proleptic appointments and the appointment of a clinical academic lead for ALS.

Professor Hanna also highlighted ION-wide EDI initiatives, including the appointment of the first EDI Deputy Institute Director, Athena SWAN Silver award renewal and relaunched website, as well as Educational achievements, including Distance Learning Programme diversity, and a UCL One PS award for David Blundred. He congratulated all our students on their recent graduation.

ION Education Prizes

Professor Hanna then announced the Annual Education prizes 2020.

  • Haymon Gorlov Prize:  Sophie Newton
  • Queen Square Essay Prize : Paul Zeun and Edwin Jabbari
  • Hugo James Ross Prize - Huda Shujaa Aldeen

Annual Address

We were delighted to welcome as the guest speaker the 2021 Breakthrough prize winner ($3m) in Life Sciences, Dr Richard J Youle, Senior Investigator in Biochemistry NINDS, Bethesda, USA, who gave a presentation entitled “Relationships between Mitophagy, Inflammation, STING and Parkinson’s Disease”

Dr Youle won this prestigious prize for his ground-breaking work on elucidating a quality control pathway that clears damaged mitochondria and protects against Parkinson’s Disease. This is a topic which is potentially relevant to many neurodegenerative diseases and therefore of great interest to the Institute of Neurology, the Faculty of Brain Sciences and the wider UCL Neuroscience community. 

The event closed with a vote of thanks by UCL President and Provost Professor Michael Arthur.

Links

2019

This year’s annual address, held on 1st October 2019, began with a review of the year’s successes presented by Professor Michael Hanna, Director of UCL Queen Square Institute of Neurology.

Professor Hanna showcased wide-ranging examples of IoN’s research impact, from the launch of a new high-dose aphasia service and research into microbleeds and anti-coagulation in stroke, to gene therapy in epilepsy, MS-STAT2 trial and MRI in MS prognosis, anti-sense studies at LWENC, work with Genomics England, and the 1946 cohort study in dementia.

He also demonstrated IoN’s impressive research output: one paper every 5 hours on average, and five a month in the world’s very highest impact journals.

Highlights from the year included:

Quinquennial review of ARUK DDI, the new 7T scanner in 12 Queen Square, 50th anniversary of Reta Lila Weston Institute, Sigrid Rausing Trust funding, IoN departmental reorganisation, including new Movement Disorders Centre, QS Genetics Therapies Centre, and launch of the QS MND Centre and the recent planning approval of the new translational neuroscience building.

These achievements were complemented by many individual IoN researchers’ awards and appointments, including an NIHR Professorship, new Fellows of the Royal Society and Academy of Medical Sciences, and the appointment of UK DRI at UCL Associate Director, alongside 100% success in 2019 senior promotions,and Teaching Awards.

Mike then announced the annual Education prizes 2019.

  • Miss Helene Marie (Nina) El-Bacha, MSc Clinical Neuroscience, Haymon Gorlov Prize
  • Dr Sabhat Iqbal, MSc in Clinical Neurology, receiving the Hugo James Ross Prize 2019 from Professor Michael Hanna (left hand image below)
  • Dr Karen Suetterlin, MRC Clinical Training Fellow, receiving the Queen Square Essay Prize 2019 from Professor Michael Hanna (right hand image below)

We were delighted that Dr C Frank Bennett delivered this year’s annual address on antisense oligonucleotide-based therapy (ASO) in neurological diseases. Dr C Frank Bennett is Senior Vice President, Research & Neurology Franchise Leader, IONIS Pharmaceuticals Inc and is co-recipient of the 2019 Breakthrough Prize for Life Sciences and recipient of the 2019 Leslie Gehry Brenner Prize for Innovation in Science.

Dr Bennett began his address with an overview of the history of neurogenetic discovery in the 1990s, and the subsequent development of new drug discovery platforms. He covered the advantages of ASO, including direct translation of genomic information into drug development, and the efficiency of the drug discovery process. Seven of these have been approved for rare diseases, with around 40 in the pipeline. IONIS have been working on neurological diseases for the past 15 years, and he showcased examples of SMA, ALS, HD and Angelman Syndrome.

He concluded with a summary of the challenges of ASO, including the potential for covering a broader range of diseases, and more patient friendly drug delivery, finishing with acknowledgements and thanks to partners, including UCL Huntington’s Disease Centre.

The event closed with a vote of thanks by Professor David Lomas, Vice Provost Health, UCL

Further information:

2018

This year’s annual address, held on 29th October 2018, began with a review of the year’s successes presented by Professor Michael Hanna, Director of UCL Queen Square Institute of Neurology.

Professor Hanna showcased wide-ranging examples of IoN’s research impact, from wearable Magnetoencephalography (MEG) to statins and MS, and gene therapy for refractive epilepsy to HD protein lowering drugs. He also demonstrated IoN’s impressive research output: one paper every 8 hours on average, and three a month in the world’s very highest impact journals.

Highlights from the year included a record turnover of over £80m and £268m current active research grants, new appointments at, and formal opening of, UK DRI at UCL, renewal of Max Planck UCL Centre for Computational Psychiatry and Ageing Research, creation of Departments of Clinical and Movement Neurosciences and Neuromuscular Diseases, rebranding as UCL Queen Square Institute of Neurology, and plans for new translational neuroscience building at EDH.

These achievements were complemented by many individual IoN researchers’ awards and appointments, including the Brain Prize (for the second successive year), NIHR Professorship, and new Fellows of the Royal Society and British Academy, alongside 100% success in 2018 promotions.

Mike then presented the annual Education prizes 2018.

We were delighted that Professor Fiona Watt FRS, Executive Chair of the MRC, delivered this year’s annual address on “My Vision for UK Biomedical Research”. Professor Watt is seconded from her post as Director of the Centre for Stem Cells and Regenerative Medicine at King’s College London, and is internationally recognised in her field, with expertise in the stem cells of healthy and diseased skin.

Professor Watt talked about her role in helping to shape the UK biomedical research landscape at this time of extraordinary transition, and her aspiration that the UK should provide the best medical research environment in the world, with superb facilities and creative funding to support excellence throughout the country.

The event closed with a vote of thanks by Professor Gill Bates (Professor of Molecular Neuroscience,  Neurodegenerative Diseases, UCL Queen Square Institute of Neurology)

Further information

 

2017

This year’s annual address, held on 7th November 2017, began with a review of the year’s successes presented by Professor Michael Hanna, Director of UCL Institute of Neurology.

Professor Hanna showcased wide-ranging examples of IoN’s research impact, from gene discovery and gene-silencing, to seizure imaging and re-purposing of drugs in Parkinson’s Disease. He also demonstrated IoN’s impressive research output: one paper every 6 hours on average, and one a week in the world’s very highest impact journals.

Highlights from the year included record research grant income at over £70m, and £248m current active research grants (2016/17), the selection of UCL as the hub of research activities and operational headquarters of the UK Dementia Research Institute, the opening of the Huntington’s Disease Centre, and renewal and rebranding of the Wellcome Trust Centre for Neuromaging. Enterprise highlights included Gold Standard Phantoms (IoN’s first start up) achieving £1m additional equity.

These achievements were complemented by many individual IoN researchers’ awards and appointments, including the Brain Prize, Weston Brain Institute International Outstanding Achievement Award, Citation Laureates, the first female ABN president, and new Fellows of the Royal Society and Academy of Medical Sciences, alongside 100% success in 2017 promotions.

Mike then presented the annual Education prizes 2017

We were delighted that Professor Bart De Strooper, Professor at the Institute of Neurology and Director of the UK DRI delivered this year’s annual address. Professor De Strooper’s major science contributions include discovering the role of presenilins in AD, the role of kinases PINK-1 and LRRK2 in PD, miRNAs in AD, and characterising the cellular phase of AD. The latter formed the basis of his Annual Address.

Professor De Strooper’s presentation emphasised the global nature of the disease, and the knowledge gap in research. He focused on 21st century methods, including single cell biology and humanised models, and future priorities in addressing the disease, drawing parallels with cardiovascular health, in terms of risk factors, early diagnosis, lifestyle and stabilisation therapy.

The event closed with a vote of thanks by Professor David Lomas (UCL Vice Provost (Health) who concluded by congratulating all at the Institute of Neurology for the past year’s successes and looking forward to UCL’s world-leading future in Neuroscience.

Further information